Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Income (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Net Income data on record, last reported at -$84.7 million in Q4 2025.

  • For Q4 2025, Net Income fell 2607.86% year-over-year to -$84.7 million; the TTM value through Dec 2025 reached $339.4 million, up 11135.11%, while the annual FY2025 figure was $339.4 million, 11095.79% up from the prior year.
  • Net Income reached -$84.7 million in Q4 2025 per TGTX's latest filing, down from $390.9 million in the prior quarter.
  • Across five years, Net Income topped out at $390.9 million in Q3 2025 and bottomed at -$94.0 million in Q4 2021.
  • Average Net Income over 5 years is -$2.9 million, with a median of -$25.1 million recorded in 2022.
  • The widest YoY moves for Net Income: up 9974.61% in 2025, down 2607.86% in 2025.
  • A 5-year view of Net Income shows it stood at -$94.0 million in 2021, then surged by 196.69% to $90.9 million in 2022, then tumbled by 114.85% to -$13.5 million in 2023, then soared by 76.84% to -$3.1 million in 2024, then plummeted by 2607.86% to -$84.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$84.7 million in Q4 2025, $390.9 million in Q3 2025, and $28.2 million in Q2 2025.